General Information

General Information

DRAVP ID DRAVPe00332

Peptide Name GF-17

Sequence GFKRIVQRIKDFLRNLV

Sequence Length 17

UniProt ID No entry found

Taxon ID None

Source Synthetic construct(derived from LL-37)

Validation Experimentally Validated

Origin Information

Gene Name/ID Not Available

GenBank Not Available

Amino Acid position Not Available

Domain Accession ID Not Available

Nucleotide sequence ID Not Available

Molecular Type Not Available

Chromosomal Position Not Available

Activity Information

Target Organism HIV, EBOV

Assay Plaque assay

Activity

[Ref.20086159]HIV-1 IIIB:inhibition the cytopathic effects of HIV-1 infection in CEM-SS cells(EC50=0.76 μM);
[Ref.18591279]HIV-1IIIB:inhibition the cytopathic effect of HIV in CEM-SS cells(EC50=0.98 μM).(EC50:50% effective concentration for inhibition of virus replication);
[Ref.32252021]Ebola Virus(EBOV):inhibition of viral infection in Hela cells(IC50=10.1 µM);inhibition of viral infection in primary macrophages(IC50>20 µM).

Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity

[Ref.20086159]CEM-SS cells:50% Cell death at 10.8 µM.
[Ref.18591279]CEM-SS cells:TC50=8.9 μM.(TC50:the concentration that reduced cell viability by 50%)

Binding Target Not found

Mechanism Act as CatB inhibitors to block the endosomal processing of EBOV GP, thus preventing virus entry.

Structure Information

PDB ID None

Predicted Structure Download DRAVPe00332

Linear/Cyclic Linear

N-terminal Modification Free

C-terminal Modification Amidation

Other Modification None

Stereochemistry L

Physicochemical Information

Formula C97H164N30O22

Absent amino acids ACEHMPSTWY

Common amino acids R

Mass 2102.56

Pl 11.72

Basic residues 5

Acidic residues 1

Hydrophobic residues 8

Net charge 4

Boman Index -4210

Hydrophobicity -9.41

Aliphatic Index 125.88

Half Life

Mammalian:30 hour
Yeast:>20 hour
E.coli:>10 hour

Extinction Coefficient cystines 0

Absorbance 280nm 0

Polar residues 2

Literature Information

Literature 1

Title Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.

Pubmed ID 20086159

Reference Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6.

Author Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.

DOI 10.1128/AAC.01448-09

Literature 2

Title Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.

Pubmed ID 18591279

Reference Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40.

Author Wang G, Watson KM, Buckheit RW Jr.

DOI 10.1128/AAC.00452-08

Literature 3

Title Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection.

Pubmed ID 32252021

Reference iScience. 2020 Apr 24;23(4):100999.

Author Yu Y, Cooper CL, Wang G, Morwitzer MJ, Kota K, Tran JP, Bradfute SB, Liu Y, Shao J, Zhang AK, Luo LG, Reid SP, Hinrichs SH, Su K.

DOI 10.1016/j.isci.2020.100999